Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

317.08 +3.67 (+1.17%)

Streaming Delayed Price Updated: 3:21 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies

December 21, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗

December 14, 2021

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...

Via Benzinga

Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 14, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021

December 02, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming Investor Conferences

November 23, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock ↗

November 22, 2021

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...

Via Benzinga

How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗

November 22, 2021

Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.

Via Investor's Business Daily

Expert Ratings For Alnylam Pharmaceuticals ↗

November 22, 2021

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

November 22, 2021

MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗

November 22, 2021

Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:

Via Benzinga

Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day

November 19, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan ↗

November 18, 2021

Novo Nordisk is buying an RNA interference company.

Via Investor's Business Daily

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021

November 13, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Virtual R&D Day

November 12, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension

November 08, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

November 05, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Named a Science Magazine Top Employer for Third Consecutive Year

November 01, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

November 01, 2021

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...

Via Benzinga

Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

ALNY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Why Alnylam Pharmaceuticals Stock Is Tanking This Week ↗

October 29, 2021

The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

66 Biggest Movers From Yesterday ↗

October 29, 2021

Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.